(Q34111460)

31 July 2017

alpha-Synuclein is phosphorylated in synucleinopathy lesions (English)

1 reference

31 July 2017

0 references

1 reference

1 reference

5

Eliezer Masliah

1 reference

31 July 2017

Hideo Fujiwara

1

1 reference

31 July 2017

Masato Hasegawa

2

1 reference

31 July 2017

Naoshi Dohmae

3

1 reference

31 July 2017

Akiko Kawashima

4

1 reference

31 July 2017

Matthew S Goldberg

6

1 reference

31 July 2017

Jie Shen

7

1 reference

31 July 2017

Koji Takio

8

1 reference

31 July 2017

Takeshi Iwatsubo

9

1 reference

31 July 2017

1 February 2002

1 reference

31 July 2017

1 reference

31 July 2017

4

1 reference

31 July 2017

160-164

1 reference

31 July 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/ncb748

31 July 2017

0 references

cites work

Alpha-synuclein in Lewy bodies

1 reference

7 January 2021

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

1 reference

7 January 2021

Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein

1 reference

7 January 2021

Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid.

1 reference

7 January 2021

Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders

1 reference

7 January 2021

alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins

1 reference

7 January 2021

Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein

1 reference

7 January 2021

Synucleins are a novel class of substrates for G protein-coupled receptor kinases

1 reference

7 January 2021

A68: a major subunit of paired helical filaments and derivatized forms of normal Tau.

1 reference

7 January 2021

Alzheimer's disease. Pinning down phosphorylated tau.

1 reference

7 January 2021

Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?

1 reference

7 January 2021

Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy

1 reference

7 January 2021

Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease

1 reference

7 January 2021

Proteomics to study genes and genomes

1 reference

7 January 2021

Proline-directed and non-proline-directed phosphorylation of PHF-tau.

1 reference

7 January 2021

Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein.

1 reference

7 January 2021

Neuronal and glial tau-positive inclusions in diverse neurologic diseases share common phosphorylation characteristics.

1 reference

7 January 2021

Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs

1 reference

7 January 2021

A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly.

1 reference

7 January 2021

Synthetic filaments assembled from C-terminally truncated alpha-synuclein.

1 reference

7 January 2021

Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein

1 reference

7 January 2021

Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.

1 reference

7 January 2021

Dimensions Publication ID

Identifiers

DOI

10.1038/NCB748

0 references

0 references

1 reference